Intellia Therapeutics, Inc. (NTLA) – What Are Researchers Saying About This Stock?

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have earned a consensus rating of “Hold” from the twenty-three analysts that are currently covering the firm, MarketBeat reports. Five analysts have rated the stock with a sell rating, eight have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $20.72.

A number of brokerages recently issued reports on NTLA. Citizens Jmp reissued a “market outperform” rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Wall Street Zen downgraded shares of Intellia Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, August 25th. Finally, Wedbush boosted their target price on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE grew its holdings in shares of Intellia Therapeutics by 11.2% during the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares during the period. Royal Bank of Canada increased its position in shares of Intellia Therapeutics by 1,082.1% during the 1st quarter. Royal Bank of Canada now owns 465,499 shares of the company’s stock worth $5,968,000 after purchasing an additional 426,121 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth about $1,595,000. BlackRock Inc. purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at about $260,721,000. Finally, Bank of New York Mellon Corp purchased a new stake in Intellia Therapeutics in the 2nd quarter valued at about $6,948,000. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Up 0.7%

Shares of NTLA opened at $11.42 on Friday. Intellia Therapeutics has a 52-week low of $7.95 and a 52-week high of $28.25. The company has a market capitalization of $1.60 billion, a PE ratio of -3.40 and a beta of 1.80. The stock has a fifty day simple moving average of $12.27 and a two-hundred day simple moving average of $13.16.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). The business had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The company’s quarterly revenue was down 46.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.98) EPS. As a group, equities analysts anticipate that Intellia Therapeutics will post -3.21 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a biotechnology company focused on developing genome-editing therapies using CRISPR/Cas9 technology. The company is working to create treatments that can directly modify disease-causing genes, including through in vivo approaches in which the editing machinery is delivered into a patient’s body.

Its pipeline has included NTLA-2001, an investigational therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational program targeting kallikrein for hereditary angioedema.